《阿斯利康(AstraZeneca):2021年可持续发展报告(英文版)(35页).pdf》由会员分享,可在线阅读,更多相关《阿斯利康(AstraZeneca):2021年可持续发展报告(英文版)(35页).pdf(35页珍藏版)》请在三个皮匠报告上搜索。
1、SustainabilityReport2021Unlocking the potential of the complement system The dysregulation of the complement system,an essential part of the immune system,is a key driver of many devastating diseases.Targeting and inhibiting the complement system before it can trigger tissue damage ordestruction can
2、 help restore balance.We are committed tocontinue unlocking the potential of the complement system,to discover new life-changing therapies for even more patients.AssuranceWe obtained external review of our sustainability performance to validate that we use the same rigour and accuracy as we do with
3、regulated reporting.Bureau Veritas has provided independent external assurance for progress on all sustainability targets and all sustainability key performance indicators shown in the Sustainability Data Summary.Details are described in the sustainability letter of assurance.Assurance was also prov
4、ided for select sustainability information in the 2021 Annual Report.Assurance is in accordance with the International Standard on Assurance Engagements 3000(ISAE 3000),and ISAE 3410 Assurance Engagements on Greenhouse Gas Statements.This report:This is our seventh annual sustainability report and i
5、t describes our approach and progress from 1 January 2021 to 31 December 2021,unless otherwise stated.The content of this report is based on those sustainability focus areas deemed material through comprehensive stakeholder engagement and analysis.Allour business operations worldwide are in scope re
6、gardless of their function,unlessotherwise stated.Online resources:AstraZeneca Sustainability Data Summary:provides performance measures and targets with at least three years of data,where available,and a United Nations Sustainable Development Goals index.AstraZeneca Sustainability webpages:cover ad
7、ditional topics of interest to our stakeholders.Infographics:show our processes and practices.Policies and company standards:state our position and guidance on key topics.2021 Annual Report:includes how sustainability is integrated across our business model and into riskmanagement.About this reportC
8、ontentsNotices 35Sustainability overview 2Leading in sustainability 3Sustainability at AstraZeneca 42021 performance highlights 5About us 6Contribution to UN SDGs 7Sustainability governance 8Stakeholder engagement 9Access to healthcare 10Overview 11Equitable access 12Affordability and pricing 14Heal
9、th system resilience 16Environmental protection 18Overview 19Ambition Zero Carbon 20Product sustainability 23Natural resources 25Ethics and transparency 27Overview 28Ethical business culture 29Inclusion and diversity 31Workforce safety and health 33Sustainability overviewAbout this reportAstraZeneca
10、 Sustainability Report 2021 2Access to healthcareEnvironmental protectionEthics and transparencyNoticesMessage from the CEOTaking action to drive sustainability is fundamental for the health of people,society,and the planet.Together with others,we have a responsibility to innovate and accelerate the
11、 delivery of sustainable healthcare in order to ensure a brighter future.2021 was another remarkable year for AstraZeneca in delivering for patients and one in which we made a significant contribution to society.Our work to tackle the biggest public health crisis of our lifetime is a testament to th
12、is,and I could not be prouder of the efforts of our employees around the world.Together with our global partners,we supplied about 2.5 billion doses of our COVID-19 vaccine to more than 180 countries during the year.Of these,approximately two-thirds went to low-and lower-middle-income countries,and
13、more than 247 million were delivered to 130 countries through the COVAX Facility,underlining our commitment to equitable access to healthcare.While it is clear that the global pandemic has had a huge impact on human health,it is essential to recognise that the effects of the climate crisis could be
14、even greater.Thats why we are taking bold action,driven by science,to reduce Leading in sustainabilityKatarina Ageborg marking the International Day of the Girl ChildMessage from the EVP,SustainabilitySustainability is part of our organisational DNA,embedded from the lab to the patient,and delivered
15、 thanks to the efforts of over 80,000 employees.We seek to create value to society beyond the impact of our medicines,and Im therefore proud of the progress that weve made throughout 2021 across our three sustainability pillars:increasing access to healthcare,protecting the environment,and demonstra
16、ting our commitment to ethics and transparency.Our leadership has been recognised externally,with inclusion in Corporate Knights ranking of the top 100 sustainable global corporations for the fifth year running.Throughout 2021,advancing inclusion and diversity has been a key focus for us;its critica
17、l to unlocking innovation as well to nurturing an ethical business culture.Our support of the Girls Belong Here initiative demonstrates our commitment in this space.Championing integrity,transparency,and fair treatment across our organisation,as well as with suppliers and partners,is also critical.2
18、022 promises to be another important year as we continue to play a leading role in building a healthy future for all and challenge ourselves to make an even bigger difference.Katarina Ageborg,EVP,Sustainability and Chief Compliance Officerour greenhouse gas(GHG)emissions and have expanded our Ambiti
19、on Zero Carbon strategy to include a net zero emissions target across the value chain by 2045.Importantly,this target is verified by the Science Based Targets initiative(SBTi)in line with their new Corporate Net Zero Standard.As you will see from this report,weve made solid progress in reducing our
20、Scope 1 and 2 GHG emissions.By the end of December 2021,we had achieved a 59%reduction in GHG emissions compared to our 2015 baseline,including the full integration of Alexions carbon footprint just months after having welcomed our new colleagues to the Group and strengthened our expertise in rare d
21、iseases.As we look ahead,increased public-private collaboration is critical to delivering net zero,patient-centric healthcare and building stronger,more resilient health systems.In 2021,we launched the second phase of our Partnership for Health System Sustainability and Resilience with the London Sc
22、hool of Economics,the World Economic Forum,and others,to strengthen health systems around the world.We also continue to work across the healthcare sector,including through the Sustainable Markets Initiative(SMI)Health Systems Taskforce,which Im proud to champion,to accelerate the decarbonisation of
23、healthcare.I am convinced that by continuing to take action and advancing purpose-driven partnerships in 2022 and beyond we can achieve system-wide change at scale to benefit patients,society at large,and our planet.Pascal Soriot,AstraZeneca CEOCEO Pascal Soriot signing the Terra Carta,a roadmap to
24、2030 for businesses to move towards an ambitious and sustainable futureLeading in sustainabilityAstraZeneca Sustainability Report 2021 3Sustainability overviewAccess to healthcareEnvironmental protectionEthics and transparencyNoticesSustainability at AstraZeneca is about using our capabilities to ma
25、ke the most meaningful impact where society needs it health.Our future depends on healthy people,a healthy society,and a healthy planet.We know that these elements are interconnected.Working in partnership with all our stakeholders,we must build a sustainable future,tackling the major issues of our
26、time.We are united by a desire to push the boundaries of science to deliver life-changing medicines and support sustainable healthcare in a way that is respectful of our planet.We are harnessing the power of science,innovation,partnership,and our global reach,to make a positive impact by embedding s
27、ustainability into everything we do.Sustainability at AstraZenecaOur sustainability strategy Our sustainability strategy is guided by a materiality assessment which we updated in 2021,inviting internal and external stakeholders to contribute their views and help us to prioritise.This assessment led
28、to a broadening of the scope of nine material focus areas where we could make the most impact,each with their own targets and commitments.Our analysis also confirmed our three interconnected strategic priorities:Access to healthcare,Environmental protection,and Ethics and transparency.Healthy planet
29、Healthy peopleHealthy societyEthics and transparencyAccess to healthcareEnvironmental protectionSustainabilityat AstraZenecaUsing our capabilities to make the most meaningful impact where society needs it health.Our sustainability approach Systems thinking we recognise that our globalised world bind
30、s us together in a dynamic,complex network of relationships.We look for opportunities that offer synergies and address systemic issues.Long-term perspective we acknowledge there are no quick fixes so we must think long-term.We anticipate,and avoid or address unintended impacts,monitoring changes ove
31、r time and building resilience.Creating the conditions for lasting sustainability we apply science to go beyond preventing and addressing any impacts from our activities to improve the environment.Our ambitions Increasing access to life-saving treatments,promoting prevention,and strengthening global
32、 healthcare resilience and sustainability.Accelerating the delivery of net zero healthcare,proactively managing our environmental impact,and investing in nature and biodiversity.Ensuring ethical,open and inclusive behaviour across our organisation and value chain.Sustainability at AstraZenecaAstraZe
33、neca Sustainability Report 2021 4Sustainability overviewAccess to healthcareEnvironmental protectionEthics and transparencyNoticesSustainability strategy2021 performance highlights 199,000+healthcare workers and others trained1(cumulative)11m+people reached though our Patient Assistance Programmes3(
34、cumulative)50.9instances of non-compliance with the Code of Ethics per thousand employees in commercial business units59%reduction in Scope 1 and 2 greenhouse gas emissions since2015 8%reduction in our waste since 201517%reduction in our water use since201531m+people reached through our access progr
35、ammes1,2(cumulative)48.1%women in senior middle management roles andaboveAccess to healthcareEnvironmental protectionEthics and transparency83%of employee survey respondents feel that AstraZeneca has a Speak Up culture49focus areas identified in our materiality assessment as priorities where we can
36、make most difference35key performance metrics measured quarterly in the internal companyscorecard 85%of employee survey respondents say that they understand their contributions to our sustainability priorities2021 performance highlightsAstraZeneca Sustainability Report 2021 5Sustainability overviewS
37、ee Sustainability Data Summary forfull metrics and methodologyAccess to healthcareEnvironmental protectionEthics and transparencyNoticesAbout usOur ValuesOur strategic prioritiesWe follow the scienceWe put patients firstWe play to winWe do the right thingWe are entrepreneurialDeliver Growth and Ther
38、apy Area Leadership Accelerate Innovative Science Be a Great Place to WorkInspired by our Values and what science can do,wearefocused on accelerating the delivery of life-changing medicines that create enduring value forpatients and society.We are a global,science-led biopharmaceutical company that
39、focuses on the discovery,development,and commercialisation of prescription medicines in Oncology,RareDiseases,and BioPharmaceuticals,including Cardiovascular,Renal&Metabolism,and Respiratory&Immunology.Based in Cambridge,UK,AstraZeneca operates in over 100countries and its innovative medicines are u
40、sed by millions of patients worldwide.Our purpose:Our recognition3,500Central and South America15,900US1,100Canada8,800UK6,900Sweden11,400Other Europe 1,600Russia1,800Middle East and Africa20,600China3,400Japan7,100Other Asia Pacific1,000Australia and New ZealandStrategic R&D centres:Cambridge,UK(HQ
41、);Gaithersburg,MD,US;Gothenburg,SwedenOther R&D centres and offices:South San Francisco,CA,US;New York,NY,US;New Haven,CT,US;Boston,MA,US;Alderley Park and Macclesfield,UK;Shanghai,China;Osaka,Japan.83,100 employees worldwideWorld and Europe Global constituent Dow Jones Sustainability Index100 Most
42、Sustainable Companies Corporate KnightsA List ClimateChange and Water Security CDP7th out of 20 Access to Medicines IndexAbout usAstraZeneca Sustainability Report 2021 6Sustainability overviewAccess to healthcareEnvironmental protectionEthics and transparencyNoticesContribution to UN SDGsThe 17 inte
43、rconnected United Nations Sustainable Development Goals(SDGs)are a global call to action,to address poverty,injustice,and inequality,whilst tackling climate change.We evaluate our contribution to the SDGs by connecting them to our targets,annualprogress,material focus areas and future strategic dire
44、ction.SDG 3|Good health and wellbeing3.4 Reduce premature mortality from NCDs5,6 3,599 health facilities activated(cumulative)through Healthy Heart Africa and Healthy Lung programmes NCD prevention information reaches 30 countries through our Young Health Programme3.6 By 2030,halve the number of glo
45、bal deaths and injuries from road traffic accidents 40%reduction in collision rate since 20153.8 Achieve universal health coverage More than 11 million people were reached by Patient Access Programmes(cumulatively)More than 31 million(cumulative)people reached through healthcare programmes 2,5,6,7 3
46、.c Substantially increase health workforce in developing countries More than 124,000 healthcare workers trained(cumulatively)6SDG 5|Gender equality 5.5 Ensure womens full and effective participation and equal opportunities for leadership at all levels of decision-making in political,economic and pub
47、lic life9 48.1%of senior roles occupied by women 38.5%of Board of Directors occupied by womenSDG 6|Clean Water and Sanitation 6.3 By 2030,improve water quality by reducing pollution,eliminating dumping and minimizing release of hazardous chemicals and materials In 2021 100%of API discharges from Ast
48、raZeneca sites and 91%from our direct suppliers demonstrated as safe11,12,13 6.4 By 2030,substantially increase water-use efficiency across all sectors and ensure sustainable withdrawals and supply of freshwater to address waterscarcity 17%reduction in water use since 2015 baseline14SDG 8|Decent wor
49、k and economicgrowth 8.8 Protect labour rights and promote safe and secure working environments for all workers 68%reduction in reportable injury rate since 201516SDG 12|Responsible consumption and production 12.2 Achieve the sustainable management and efficient use of natural resources 75%of new pr
50、oducts have met their defined resource efficiency targets at launch since 20151012.5 By 2030,substantially reduce waste generation through prevention,reduction,recycling and reuse 8%decrease in total waste generation since 2015 baseline14,15 In 2021,avoided 999 tonnes of waste by selling it as a by-
51、productSDG 13|Climate action 13.2 Integrate climate change measures into national policies,strategies and planning Reduced Scope 1 and 2 emissions by 59%since 20158 Scope 3 emissions increased by 15%since 2019SDG 7|Affordable and CleanEnergy 7.3 By 2030,double the global rate of improvement in energ
52、y efficiency 64%increase in EP 100:Energy productivity(USD revenue per MWh)SDG 17|Partnership for the goals 17.17 Encourage and promote effective public,publicprivate and civil society partnerships Launched phase two Partnership for Health System Sustainability and Resilience(PHSSR)SDG 15|Life on La
53、nd 3,430,061 trees were planted since 2020 through AZ Forest 2022 target:Ensure 95%of paper-based product packaging materials used are supplied from sustainable sourcesContribution to UN SDGsAstraZeneca Sustainability Report 2021 7Sustainability overviewAccess to healthcareEnvironmental protectionEt
54、hics and transparencyNoticesSustainability governanceOur governance organisationA number of different stakeholders provide governance over our sustainability progress,helping to ensure that we stay on track and move forward in the most impactful way.Leif Johansson BODNon-Executive Chairman of the Bo
55、ardPascal Soriot BODSETCEO and Executive Director of the BoardNazneen Rahman BODBSCNon-Executive Director of the Board and Chair of the Sustainability CommitteeAndreas Rummelt BODBSC Non-Executive Director of the Board Sheri McCoy BODBSCNon-Executive Director of the BoardMarcus Wallenberg BODBSCNon-
56、Executive Director of the BoardKatarina Ageborg SETEVP,Sustainability and Chief Compliance Officer,President AstraZeneca AB,SwedenBoard of DirectorsThe AstraZeneca Board of Directors reviews our internal sustainability scorecard each quarter.During 2021,Nazneen Rahman,Non-Executive Director,oversaw
57、sustainability on behalf of the Board,until the creation of the Board Sustainability Committee in September 2021,which she chairs.Senior Executive Team(SET)The Senior Executive Team,made up of our CEO Pascal Soriot and company leaders who report into him,is accountable for specific sustainability in
58、itiatives and reviews our internal sustainability scorecard each quarter.Katarina Ageborg,EVP Sustainability and Chief Compliance Officer,is responsible for the overall sustainability strategy execution,including measuring progress on targets and working with company leadership to ensure alignment w
59、ith business priorities.Board Sustainability CommitteeIn 2021,the Board set up a Sustainability Committee17 to monitor the execution of our sustainability strategy,oversee communication of sustainability activities with stakeholders,and provide input to the Board and other Board Committees on sustai
60、nability matters.The Non-Executive Board members of the Committee are NazneenRahman(Chair),Sheri McCoy,Andreas Rummelt andMarcus Wallenberg.Standing attendees at Committee meetings include the EVP,Sustainability&Chief Compliance Officer,the EVP Operations&IT,and the VP Global SHE&Operations Sustaina
61、bility.BODBoard of DirectorsBSCBoard Sustainability CommitteeSETSenior Executive Team(SET)Sustainability governanceAstraZeneca Sustainability Report 2021 8Sustainability overviewAccess to healthcareEnvironmental protectionEthics and transparencyNotices2021 Materiality assessment focus areasStakehold
62、er engagement in action Our key stakeholder groups include the following:We value the diverse perspectives of internal and external stakeholders,which help to shape our sustainability strategy and guide its implementation.We welcome transparent dialogue via a range of communication channels online,f
63、ace to face and in groups.Our Code of Ethics guides our approach and you can read more about how anyone can raise concerns here.Materiality assessment In 2021 we refreshed our previous materiality assessment,which guides our sustainability strategy by identifying the issues that matter most to Astra
64、Zeneca and our stakeholders,and shows where we can have the most positive impact.We also assess our strategy against emerging trends and through what we learn from all our stakeholder engagements.In collaboration with an independent consultancy,and with the directional guidance of our Sustainability
65、 Advisory Board(SAB)18,our 2021 materiality assessment refined how we define our priorities and broadened the scope of nine focus areas.Each material focus area is detailed in this report,along with the relevant targets and goals,illustrated by examples of sustainability in action from our 2021 acti
66、vities.Following this exercise,it was agreed that the SAB had fulfilled its remit.Stakeholder engagement Patients:We engage with patients,caregivers and patient advocacy organisations representing the diverse populations that our medicines may serve.We embed these insights to ensure that the medicin
67、es and services we develop have the greatest impact on their lives.See Access to healthcare for examples.Communities:We aim to make a positive impact on people in all the communities where we are present,supporting programmes to advance patient health,increase access to care,drive scientific innovat
68、ion and build resiliency.In 2021,we provided$112.9m to more than 1,220 non-profit organisations across 74 countries.Government bodies and regulators:We partner with stakeholders on a global,regional and local level on shared objectives and health priorities.Through public-private collaboration,we ar
69、e helping to address societal and health challenges such as the pandemic response,health system resilience and climate change and are committed to making a sustainable impact.Healthcare professionals(HCPs):We rely on HCP insights to improve how we develop and deliver our medicines to patients.We eng
70、age with HCPs through advisory boards,clinical trials and educational events and congresses.In 2021 we responded to 118,000 HCP enquiries and processed over 60,000 adverse event reports from HCPs.Suppliers:We depend on integrated supply chains and third-party providers to produce and deliver medicin
71、es to patients across the world.Our partners make a critical contribution to achieving our sustainability goals.We also partner with them to promote ethical practices and support their sustainability journey.Employees:We hold employee engagement events on our sustainability agenda and create opportu
72、nities for employee action,including through our Sustainability&Me global employee campaign as well as during AstraZenecas Patient Week,Power of Diversity Week,and on the International Day of the Girl.Analysts,investors,and ratings agencies:We share periodic sustainability-related updates with analy
73、sts,institutional investors and rating agencies,through direct outreach and in a dedicated section within our full-year and quarterly results announcements and presentations.In 2021,we hosted 40 sustainability-focused events.Stakeholder engagementAstraZeneca Sustainability Report 2021 9Sustainabilit
74、y overviewAccess to healthcareEnvironmental protectionEthics and transparencyEquitable accessAffordability and pricingAmbition Zero CarbonProduct sustainabilityNatural resourcesEthical business cultureInclusion and diversityWorkforce safety and healthEnvironmental protectionEthics and transparencyHe
75、alth system resilienceAccess to healthcareNoticesAccess to healthcareOur ambition:Increasing access to life-saving treatments,promoting prevention,and strengthening global healthcare resilience and sustainabilityConnection to health:Innovative and sustainable healthcare solutions are essential to im
76、proving global healthoutcomesHealth is key for people,planet and business tothriveContributing to the Sustainable Development Goals,a universal blueprint for prosperity forpeople and the planet,now and intothe future.SDG 3|Good health and wellbeingSDG 17|Partnerships for the goals199,000+healthcare
77、workers and others trained1(cumulative)31m+people reached through our access programmes1,2(cumulative)11m+people reached though our Patient Assistance Programmes3(cumulative)2021 performance:Our material focus areas3,500+healthcare facilities activated1Access to healthcareAstraZeneca Sustainability
78、Report 2021 10Access to healthcareSee Sustainability Data Summary forfull metrics and methodologySustainability overviewEnvironmental protectionEthics and transparencyEquitable accessAffordability and pricingHealth system resilienceNoticesWe want to help secure a future where all people have access
79、to affordable,sustainable healthcare.Thisis critical for the prevention and early diagnosis of disease aswell as delivering life-changing treatments for healthy people and ahealthy society.The big picture We recognise health as a human right.Healthcare is our core business;our purpose is to push the
80、 boundaries of science to deliver life-changing medicines.The development and supply of our COVID-19 vaccine put broad and equitable access at the heart of our pandemic response.Together with our global partners,we supplied about 2.5 billion vaccine doses to more than 180 countries in 2021.Of these,
81、approximately two-thirds went to low-and lower-middle-income countries,and more than 247 million were delivered to 130 countries through the COVAX Facility in 2021.ApproachAt AstraZeneca,we are committed to supporting society through some of its toughest healthcare challenges.We work in collaboratio
82、n with governments,academia,international and local organisations,and other stakeholders and we always put patients first.We provide healthcare solutions across the patient care pathway from prevention,raising awareness,diagnosis and treatment,to post-treatment.We are focused on:Innovating to delive
83、r life-changing medicines and future-proof global healthsystems Partnering to improve health equity for patients now and in thelong-term Transforming healthcare to ensure everyone has equitable access to treatmentGovernanceWe collaborate on our Access to healthcare material focus areas on a cross-fu
84、nctional basis to deliver our strategy and measure progress.Access to healthcare overview Material focus areasWorking towards a future where all people have access to sustainable healthcare solutions for life-changing treatment and preventionInnovatingTransformingPartneringPatientsAccess to healthca
85、re overviewAstraZeneca Sustainability Report 2021 11Access to healthcareSustainability overviewEnvironmental protectionEthics and transparencyEquitable accessAffordability and pricingHealth system resilienceNoticesWhy it mattersYour health should not be determined by who you are,where you live or wh
86、ere you were born.We are working to remove barriers to healthcare and give everyone the chance to be as healthy as possible.Thisincludes supporting the development,and improving delivery of healthcare,particularly in low-and middle-income countries.DescriptionEmbedding practices into our product por
87、tfolio to drive equitable access to healthcare including digital health,clinical trial diversity,patient centricity,investment in rare diseases,open innovation and IP-sharing arrangements.ApproachAstraZeneca is committed to equitable access to healthcare for patients globally.Our approach includes a
88、dapting our programmes to integrate into local systems and delivering affordable medicines to patients.We work on a cross-functional basis to develop an innovative product portfolio that drives positive global health outcomes to:Address unmet medical needs and barriers to access Increase the speed a
89、nd breadth of patient access Drive excellence in product life cycle management Understand the long-term impacts of scientific advances As a science-led,patient-focused organisation,we have an obligation to play our part in addressing health inequities and eliminating discrimination from the delivery
90、 of healthcare.This includes harnessing the power of data and analytics to transform medicines development and improve patient outcomes and experience through the use of digital technology in R&D.We are committed to ensuring that our clinical trials represent the diversity of the communities we serv
91、e,by embedding diversity and inclusion parameters into the entire clinical development life cycle.This includes a diverse geographical selection for clinical trial development,as well as early access and continued post-trial access for clinical trial participants.We collaborate to advance scientific
92、 understanding and build local capacity for R&D,as well as consider how our products will affect the populations they intend to treat within the R&D phases through our work on product safety and environmental stewardship.We also consider the range of ethical patient access issues that arise from bio
93、logical and medical science.ChallengesOur access programmes in low-and middle-income countries are tailored to meet the needs of the healthcare systems,patients and communities they serve.We identify barriers to care and contribute towards health system strengthening by training providers and addres
94、sing gaps in awareness,education,prevention and diagnosis.To address some of the challenges of healthcare inequity highlighted during the pandemic,we re-aligned our access initiatives to meet local needs through:Improving diversity in clinical trials Focusing on equitable pricing strategies to meet
95、varying incomelevels Collaborating in cross-sector partnerships to improve health outcomesEquitable access2025 targetReach 50 million people(cumulatively)through Healthy Heart Africa,Young Health Programme(YHP),and Healthy Lung programmesStatus:On Plan2021 updateMore than 31 million people reached(c
96、umulatively)through Healthy Heart Africa,Young Health Programme and Healthy Lung programmes1,2Philanthropy 2021 update$112.9m total community investment,sponsorships,partnerships and charitable donations(not including Patient Assistance)Key targets and progressEquitable accessAstraZeneca Sustainabil
97、ity Report 2021 12Access to healthcareSee Sustainability Data Summary forfull metrics and methodology.Sustainability overviewEnvironmental protectionEthics and transparencyNoticesHighlightsAccelerating Change Together(ACT)on Health Equity In 2021,AstraZeneca US launched a five-year initiative to ide
98、ntify and invest in solutions to advance health equity in partnership with the external community.ACT on Health Equity is a natural extension of our longstanding values to follow the science and put patients first.Living these values requires that we increase our focus on closing the gaps in health
99、outcomes impacting historically excluded and disenfranchised populations.The initiative balances an urgency to act with the desire for long-term sustainable change.Key accomplishments in the inaugural year include:the creation of a Health Equity Advisory council to provide ongoing external expertise
100、,more than$4m in new strategic collaborations with non-profits advancing health equity in our core therapeutic areas and at the community level,and opportunities for employees company-wide to make an impact.Global initiatives to better understand clinical trial diversityIn 2021,we made progress in b
101、uilding a foundation for our commitment to clinical trial diversity:We reviewed and updated processes and systems allowing capture and further analysis of demographic parameters such as patient race and ethnicity We are actively contributing to industry partnerships,such as PhRMA and TransCelerate,t
102、o advance clinical trial diversity initiatives and build inclusive community-based partnerships that serve underserved communities We were one of 23 companies that contributed to a study by the Tufts Center for the Study of Drug Development(TCSDD)on increasing diversity in clinical trials,which was
103、delivered in October 2021.This was conducted on a global and cross-industry basis to gather baseline measurement of clinical research staff diversity at investigative sites globally,and to identify opportunities to better engage with and enable them in the successful execution of clinical trials.Ove
104、r 3,462 investigative site personnel took part We developed and tested a bespoke diversity measurement tool,built on updated data systems and infrastructure,to be implemented in all new trials by the end of 2022 Alexion,AstraZenecas Rare Disease Group,established an Innovation Pod focused on clinica
105、l trial diversity with a cross-functional team of subject matter experts,working in partnership with R&D leadership,to embed a diverse and equitable mindset into trial design and recruitment to better address health inequities within our rare disease global patient communities.The team aspires to tr
106、ack diversity in all of our Phase II-III clinical studies,as well as have real-world representation in our clinical programmes.In 2021,the focus was on analysing and understanding current status,and raising awareness of why diversity in clinical trials is important,both internally and externallyThe
107、home of patient-enabled innovation A.Catalyst Network is a global network of more than 20 AstraZeneca health innovation hubs,made-up of physical locations and partner ecosystems.It brings togethertraditional(patients,healthcare practitioners,governments and policy makers,academia)and non-traditional
108、(tech and fintech,pharma companies,ecosystem builders,founders and investors)partners to advance equitable access to affordable,high-quality and innovative solutions.Through this network,we are co-creating challenge-based solutions with,and for,patients,and are working with partners to establish int
109、egrated and strong health systems that benefit the whole patient experience.By the end of 2021,we had established more than 400 partnerships,over 80 of which were long-term partners,with a further seven anchor partners who helped us set up the hubs,including Slush the worlds largest start-ups commun
110、ity.Together we have reached more than 730,000 patients,influenced more than 110 projects and partnerships aligned with our product and access strategies,and mentored more than 240 start-ups,helping to scale 11solutions.In 2021,we announced a joint venture with the UK Royal Academy of Engineering to
111、 strengthenhealthcare innovation,nurture local talent and boost economic progress across Africa.We also expanded our partnership with Bitgenia to cover the whole of Latin America.The ColGenBio platform aims to improve treatment outcomes by enabling the matching of life-changing medicines with the pa
112、tients most likely to benefit.AI-powered solutions for early disease detection in emerging marketsWe partner with companies specialising in artificial intelligence(AI)solutions to enable early diagnosis and intervention,and improve cure rates for some of the most important disease areas including lu
113、ng cancer,chronic obstructive pulmonary disease(COPD)and congestive heart failure.One example is our partnership withQure.ai,developers of deep learning algorithms for the interpretation of radiology images.We use their qXR AI-based comprehensive chest X-ray software to automatically detect clinical
114、ly relevant findings.This partnership aims to integrate AI solutions for the early detection of lung cancer in patients in multiple emerging markets across Latin America,Asia,the Middle East and Africa.Results so far include lung cancer detection in 13 countries,with 2-3%of nodules detected in appro
115、ximately 10,000scans.We have similar partnerships withPredibleand Botkin.AI.Sustainability in actionInvesting in supporting the rare disease communityAlexions Diagnostic Center of Excellence works to address the unmet medical needs of the rare disease community.Most rare diseases have a genetic comp
116、onent and the majority of people with a rare disease remain undiagnosed on average waiting almost five years and seeing over seven specialists3,which is unacceptable.One example of progress in this space is Wilson disease(WD)a genetic disorder that requires life-long therapy and is often misdiagnose
117、d until patients have significant symptoms.In partnership with our Bioinformatics and Data Science group and Genomenon,we are providing a curated database of genetic variants for the gene that is a driver for WD.This partnership will benefit patients by organising,interpreting and making broadly ava
118、ilable genetic information on WD.Equitable accessAstraZeneca Sustainability Report 2021 13Access to healthcareEnvironmental protectionEthics and transparencySustainability overviewNotices2021 update1,220 non-profit organisations funded by AstraZeneca2021 update$2,351.5m in product donation through P
119、atient Assistance Programmes3Why it mattersWe want all patients who need our medicines to be able to access them without suffering financial hardship.We are constantly looking at ways to make our life-changing medicines widely available and accessible to people around the world.There is no single so
120、lution making progress here will require our industry,policymakers and payers to address the barriers to access and affordability together.DescriptionDrive accessibility of medicines for diverse,equitable and inclusive patient groups,through company policy and programming,including core pricing prin
121、ciples and access programmes.ApproachWe take a broad approach to reflect the wide variation in global healthcare systems,working closely with payers,policymakers and non-governmental organisations to ensure access is both widespread and sustainable.A variety of approaches and programmes are tailored
122、 to address local needs,working together with local healthcare systems.These have the aim of both improving their resilience and supporting sustainable access to,and affordability of,healthcare.Our medicines help address unmet medical needs,improve health and create economic benefits.Because each he
123、althcare system is unique,with different healthcare costs,patient populations and societal priorities,the value of medicines in a particular healthcare system is also different.We believe that the price of a medicine should reflect its value,support sustainability,maximise patient access and provide
124、 flexibility to accommodate differences in global health systems and the economic realities for patients.ChallengesOperating in more than 100 countries worldwide means that most of our key markets have experienced the implementation of various pricing controls,reimbursement mechanisms or cost-contai
125、nment measures.We expect ongoing downward pressure on prices globally,affecting the profitability levels of our medicines in various markets.Related challenges include:the frequency of regulatory changes;price controls that reduce flexibility and our ability to apply discounts;supply chain complexit
126、y adding to the cost of medicines;the impact of economic downturns on ability to pay,where applicable;and lack of health system infrastructure in low-to middle-income countries to enable tracking of outcomes for value-based agreements.Affordability and pricingProgress highlightsAffordability and pri
127、cingAstraZeneca Sustainability Report 2021 14Access to healthcareSee Sustainability Data Summary forfull metrics and methodology.Environmental protectionEthics and transparencySustainability overviewNoticesHighlightsFazBem programme continues to grow in BrazilOur FazBem programme has been in operati
128、on since 2008,when it first offered medicines at a discounted price in Brazil.Additional services and patient communications have been added and over three million patients have been reached.In 2021 there were over 693,000 patient purchases and FazBem is present in more than 45,000 pharmacies.Addres
129、sing barriers for severe asthma patients in UAEThis 360 Patient Support Programme addresses the main barriers and challenges facing severe asthma patients in the Gulf,and improves their patient journey by connecting them with their healthcare professionals and nurses through a digital platform.More
130、than 85%of the United Arab Emirates population have partial or limited access to innovative products due to lack of insurance coverage or high co-payment levels.The programme offers a variable cost sharing patient assistance programme,customised based on each patients ability to pay,which is assesse
131、d by a deep financial evaluation implemented by a third party to determine the treatment plan.The treatment cost is shared by the patient and/or their insurance,non-governmental organisations and AstraZeneca,to ensure the sustainability of the programme.UHC2030 AstraZeneca has become a private secto
132、r partner of the UHC2030 global movement to build stronger health systems for Universal Health Coverage(UHC).This is in line with our commitment to work together to accelerate progress towards UHC,through building andexpanding equitable,resilient and sustainable health systems,in line with the UHC20
133、30 mission.Making genetic testing for ovarian cancer affordable We have entered into a partnership with a diagnostics company called AmoyDx to make genetic testing for ovarian cancer more affordable.Our goal is to improve access to testing which identifies homologous recombination deficiency(HRD),a
134、biomarker for cancer.Building on our bridging programme for advanced ovarian cancer(AOC),patients in eight regional referral hubs in Asia(Singapore-Lucense and Malaysia-Pantai and India-Strand Life Sciences),Latin America(Brazil-Pardini),Russia(02 Research Centres for MG)and Middle East and Africa(E
135、gypt-Anwaa and Greece-Genotypos)in 2021.The programme supports patients until they have HRD testing reimbursement,with the company covering the cost of testing in more than 20 countries around the world.Outcomes in 2021 65%reduction in cost of HRD testing+27%increase in tests,through eight regional
136、referral hubs Change ofpractice in AOC,allowingfor thecorrectdiagnosis andappropriatetreatment ofwomenwith AOC The project is facilitating,promoting and supporting the establishment of HRD labs at an affordable cost Sustainable innovative therapies for lung cancer The initial focus of this programme
137、 was a targeted therapy for lung cancer,with a clear objective of optimising access in low-to middle-income countries through an access-driven reimbursement programme.The initiative was based on four pillars:Revisit pricing approach Explore specific vehicles to accelerate implementation(financing,se
138、cond brand,non-governmental organisations)Shape policy to improve cancer coverage and drive implementation of cancer screening and diagnosis Invest in strategic input at a global level and capability at the market levelThe project will initially be implemented in six markets:Mexico,Brazil,Vietnam,Ma
139、laysia,India and Egypt.In collaboration with the International Market Access Team,each market has identified local needs,including diagnostics,patient support programmes,resourcing and capability assessment.This initiative will reach more than 10,000 additional patients in the next five years,includ
140、ing in other International markets.PUMUA initiative redefining asthma careinAfricaLaunched in Africa in 2020,the PUMUA Initiative is committed to redefining asthma care PUMUA is a Swahili word that means breathe.Through our partnership with governments,healthcare professionals and national respirato
141、ry societies,the initiative aims to improve paediatric and adult asthma management across public and private sectors with a focus on:Local health system strengthening Health worker capacity building Awareness and education Equitable access to our respiratory medicines As part of our commitment to im
142、prove accessibility and affordability of quality care in Africa,the PUMUA initiative makes low-cost,high quality respiratory medicines available as part of the programme at a significant discount in Kenya and Ghana.The programme also makes respiratory equipment for asthma management available in all
143、 participating countries.In 2021,the programme activated 800 nebulisation stations in Kenya,Ghana,Cte dIvoire,Ethiopia and Senegal.Sustainability in actionAstraZeneca Sustainability Report 2021 15Affordability and pricingAccess to healthcareEnvironmental protectionEthics and transparencySustainabili
144、ty overviewNoticesWhy it mattersSustainable healthcare for all requires investment in strengthening health systems,to deliver an infrastructure designed to be responsive to the needs of the population it serves.During the COVID-19 pandemic,we have seen the need for health systems to adapt to ever-ch
145、anging societal and economic circumstances and cope with shocks and crisis situations.All while continuing to provide services and deliver improved health outcomes,particularly in low-and middle-income countries.DescriptionStrengthen health systems by advocating for health system reform and policy;b
146、uilding capabilities to address unmet medical need,improve access to quality healthcare and provide solutions along a continuum of care-from prevention,awareness,diagnosis,treatment to post-treatment and wellness;and committing to disaster relief,grants anddonations.ApproachEven before the impact of
147、 COVID-19,many health systems had significant limitations in reaching those with unmet medical needs.The pandemic has revealed and exacerbated such pre-existing weaknesses and demonstrated the urgent need to build more resilient health systems worldwide.Each of our Access to healthcare focus areas c
148、ontributes to health system resilience and we are investing in ground-breaking global collaborations,local partnerships,company initiatives and fast-tracked innovation to give access to,and improve the quality of,healthcare for more people.Specific activities include:Improving preparedness for futur
149、e shocks and enhancing international coordination on key processes such as scenario planning,response protocols and reserve capacities Optimising the location and focus of care on patients using digital technologies Addressing the unsustainable social,economic and ecological costs of disease through
150、 targeted prevention measures Improving the effectiveness of care for chronic diseases through defining,implementing and monitoring improved quality of care standards The nature of diseases and infection and their risk factors calls for multi-sector involvement in prevention and control measures.We
151、work with stakeholders to align on our shared objectives and develop interventions that are optimised to address local challenges,while leveraging our experience in health programming We aim to build the capabilities of healthcare systems to best respond to patient needs by:Remaining culturally rele
152、vant and ensuring programming is locally appropriate Using our global footprint to scale partnerships Establishing mechanisms for collaboration with our partners,for example through joint coordination,planning,follow up and agreement of a set of core indicators for monitoring and evaluationChallenge
153、sCOVID-19 disrupted essential health services in 90%of countries.There are some signs of recovery emerging,but disruption continued into 2021,and major efforts are still required to restore and strengthen health systems.66%of countries reported workforce-related health reasons as the most common cau
154、se of service disruption.Our access programmes focus on strengthening healthcare systems through training of healthcare providers,a key ingredient in combating health crises and in building sustainable health systems.Key targets and progressHealth system resilience2025 targetTrain 170,000 healthcare
155、 workers(cumulatively)to strengthen health systems throughout the world through our Healthy Heart Africa and Healthy Lung programmesStatus:On Plan2021 updateMore than 124,000 healthcare workers trained(cumulatively)1,2Health facilities activated1 2021 updateMore than 3,500 healthcare facilities(cumu
156、latively)were activated through our Healthy Heart Africa and Healthy Lung programmesHealth system resilienceAstraZeneca Sustainability Report 2021 16Access to healthcareSee Sustainability Data Summary forfull metrics and methodology.Environmental protectionEthics and transparencySustainability overv
157、iewNoticesHighlightsUNGC Belt and Road Initiative We have joined the United Nations Global Compact“Sustainable Infrastructure for the Belt and Road Initiative to Accelerate the SDGs”Action Platform.Through this international cooperation we will work to improve healthcare infrastructure in Belt and R
158、oad countries in Asia,Central and Latin America,and the Middle East and Africa.We are exploring an innovative collaboration model to drive cancer screening and diagnosis programmes,focusing on lung,breast and prostate cancer,partnering with local stakeholders and building on our existing Lung Ambiti
159、on Alliance coalition and local oncology access programmes.i-Breathe initiative in EgyptIn Egypt,we are working to improve management of pulmonary diseases including asthma and chronic obstructive pulmonary disease(COPD),and early detection of lung cancer.With the Ministry of Health and the Egyptian
160、 Scientific Society of Bronchology,we are shaping the patient journey through a digitised network referral system between chest hospitals and oncology centres.So far,26 hospitals have been established and activated,500 healthcare professionals trained in the updated protocols and GINA guidelines(Glo
161、bal Initiative for Asthma management and prevention),and we have helped to shape policy through a white paper on asthma management in Egypt.European expert group on Orphan Drug IncentivesAt the European level,in 2021 we established and co-led the European Expert Group on Orphan Drug Incentives and l
162、aunched our engagement platform,Rare Conversations,to forge stakeholder dialogue on research in rare diseases.Sustainability in actionHealthy Heart Africa(HHA)Launched in 2014,our HHA programme is committed to tackling hypertension and the increasing burden of cardiovascular disease,with the ambitio
163、n to reach 10 million people with elevated blood pressure across Africa by 2025.HHA supports local health systems by increasing awareness of the symptoms and risks of hypertension,and by offering health education,screening,reduced-cost treatment and control.In 2021,the HHA programme expanded into Ct
164、e dIvoire and Senegal,with agreement to launch in Rwanda.Since launch,HHA has conducted over 23 million blood pressure screenings,identified over four million elevated readings,activated over 950 sites,and trained over 9,000 healthcare workers.This programme is now operating in eight countries in Ea
165、st and WestAfrica.Young Health Programme(YHP)Since 2010,our YHP has empowered young people aged 10-24 to take control of their health,especially to combat non-communicable diseases(NCDs),including mental health.In partnership with UNICEF,Plan International and One Young World,we support research,adv
166、ocacy,education and leadership development to help young people make better choices for healthier lives.In 2021,YHP reached over 1.1 million young people with health information and trained over 53,000 advocates in 30 countries.Independent three-to five-year impact assessments on programming in Braz
167、il,Indonesia and Kenya and in India confirmed that YHPs community-based model supports sustained behaviour change and improves access to adolescent-friendly health services.Our programmes deliveringon the journey to our target of 50 million people reached by 2025 Our programme teams work in collabor
168、ation with local and global stakeholders and implementing partners to strengthen and protect health systems.They offer training to healthcare providers,promote health education and awareness-raising activities,and facilitate access to treatment where appropriate.Partnership for Health System Sustain
169、ability and Resilience(PHSSR)Launched in 2020,the PHSSR a collaboration between the London School of Economics,the World Economic Forum and AstraZeneca continued its work to strengthen global health systems,through and beyond the COVID-19 pandemic.The PHSSRs interim report was published in March 202
170、1 at a virtual summit attended by over 1,500 people from 65 countries.The PHSSR phase two was launched in 2021,with an expansion into 13 new countries and a regional hub in the Central,Eastern Europe and Baltics Area,bringing the total number of PHSSR member countries to over 30.The PHSSR has acted
171、as the basis for policy improvements in many of the countries where it has been active.For example,in Germany,it underpinned the reform of screening and prevention programmes,and in Poland and Italy,the PHSSR supported these governments in designing improved chronic care models.On the global stage,t
172、he PHSSRs recommendations contributed to a key input to the B20-G20 dialogue on health and lifesciences.BelgiumBrazilJapanPortugalCanadaEgyptGreeceIndiaIrelandThe NetherlandsSaudi ArabiaSouth AfricaSwitzerlandIn 2021 we launched phase two of the PHSSR,expanding into 13 new countriesAstraZeneca Susta
173、inability Report 2021 17Health system resilienceAccess to healthcareEnvironmental protectionEthics and transparencySustainability overviewNoticesEnvironmental protectionOur ambition:Accelerating the delivery of net zero healthcare,proactively managing our environmental impact,and investing in nature
174、 and biodiversityConnection to health:Supporting a healthy environment helps prevent the onset of certain diseases andimprove health outcomesThe health of the planet impacts all life worldwide Contributing to the Sustainable Development Goals,a universal blueprint for prosperity forpeople and the pl
175、anet,now and intothe future.SDG 6|Clean water and sanitationSDG 7|Affordable and clean energySDG 12|Responsible consumption and productionSDG 13|Climate actionSDG 15|Life on landSDG 17|Partnerships for the goals1 of 7companies to have climate targets verified to new science-based Net Zero Corporate
176、Standard100%Imported renewable electricity4brands included in internal pilot of Product Sustainability Index(PSI)100%safe API discharges for AstraZeneca sites and 91%for supplier sites1,2,3Our material focus areas2021 performance:Environmental protectionAstraZeneca Sustainability Report 2021 18Envir
177、onmental protectionSee Sustainability Data Summary forfull metrics and methodologyAccess to healthcareEthics and transparencyAmbition Zero CarbonProduct sustainabilityNatural resourcesSustainability overviewNoticesThe relationship between human and planetary health is complex and interdependent,with
178、 society and nature having a significant impact on one another.The climate emergency,the loss of habitats and biodiversity,water scarcity and declining water quality,plastics pollution and dwindling finite resources all threaten public health and the environment.We have a collective responsibility t
179、o create a more sustainable world for people and the planet together and without delay.The big picture The environmental challenge is multifaceted,and our material focus areas cannot be managed in isolation.Sustainable product design,sourcing and manufacture leads to lower natural resource use,reduc
180、ed chemical and water demand,less waste and pollution,and can significantly reduce our carbon footprint.There is also an increased focus on the environmental footprint of goods and services and companies are under greater environmental scrutiny,reinforcing the need to have robust scientific evidence
181、 underpinning environmental targets andperformance.ApproachWe are using a science-led,patient-centric approach to discover innovative solutions which will help to lower the economic and environmental burden of healthcare.This will help build more sustainable,resilient health systems.It is clear from
182、 the 2021 IPPC report that the latest science is telling us we are at a critical point,and we must all increase our efforts to limit the impacts of the climate crisis on our planet.A systems-level approach is needed to deliver better healthcare outcomes with a lower environmental footprint.We recogn
183、ise that working in partnership is critical to achieving this,which is why we are a founding member of HRH The Prince of Wales Sustainable Markets Initiative,where Pascal Soriot our Chief Executive Officer is championing the newly launched Health Systems Taskforce.The commitment by 50 countries at t
184、he World Health Organization-led COP26 Health Programme to develop climate smart healthcare is another strong example of the power of collaboration.GovernanceIn addition to our general approach to governance,our executive-led Ambition Zero Carbon Governance Group is accountable for the delivery of o
185、ur Ambition Zero Carbon strategy.This high-level group includes our CEO,CFO,the EVP,Sustainability and Chief Compliance Officer,and the EVP,Operations and IT.The guide for our Environmental Management System our global safety,health,and environment management principles is embedded in our Code of Et
186、hics supported by a new SHE policy standard.It involves key activities to manage our environmental risks,operational standard procedures,an audit programme led by an independent organisation according to ISO standards,and an annual management review process.ISO 14001(environmental management),(repre
187、senting 16%of employees covered):in Shanghai,China;Milan,Italy;Macclesfield,UK;Gothenburg and Sdertlje,Sweden ISO 50001(energy management),(representing 27%of total energy consumption):in Macclesfield,UK,and Gaithersburg,USNatural Resource EfficiencyFundTo drive our natural resource and greenhouse g
188、as(GHG)reduction initiatives at our sites to support our environmental targets,we have a dedicated fund managed by a governance group to target investments across the enterprise that maximise the resource benefits as well as financial returns.This fund has invested more than$130m in environmental ef
189、ficiency innovations since 2015,including 56 new projects and$30m spent in 2021.Continued support for these efforts is ongoing,with$25m spend allocated for additional efficiency projects in 2022.Environmental protection overview TCFD Task Force on Climate-Related Financial DisclosuresA TCFD steering
190、 group with cross-functional membership has oversight of the physical and transitional risks and opportunities posed to AstraZeneca by climate change.We have integrated climate risks into our overall risk management process,recognising climate risk as a stand-alone risk since we published our full T
191、CFD statement in 2021.We are incorporating climate resilience across our operations and value chain,mitigating the risks,and exploring the opportunities that the transition to a low carbon economy presents to the healthcare sector.Material focus areasEnvironmental protection overviewEnvironmental pr
192、otectionAstraZeneca Sustainability Report 2021 19Access to healthcareEthics and transparencyAmbition Zero CarbonProduct sustainabilityNatural resourcesSustainability overviewNoticesOur Scope 3 footprint is more than 20 times greater than our Scope 1 and 2 footprint and our ambitions will only be ach
193、ieved through close collaboration with our supply chain partners.This is why we have set the goal to maximise the share of our spend that is with companies with verified science-based targets(SBTs),and we work closely with the SBTi and our peers to support the progression to a low carbon economy.Cha
194、llengesSupplier maturity on climate issues varies greatly,creating challenges in effective communication of our expectations of suppliers,for example to understand the full value chain emissions associated with our share of a suppliers business.Supporting suppliers on this journey,for instance to se
195、t and achieve reductions aligned with their SBTs,is resource-intensive and it is a challenge to scale to a significant proportion of the supply chain.Access to renewable sources of heat,as well as electric vehicles and associated infrastructure in some developing markets,will continue to be a challe
196、nge,impacting both the environment and health in these communities.Why it mattersWe are taking bold action on climate because we recognise the connection between healthy people and a healthy planet.The COVID-19 pandemic has resulted in the greatest public health challenges of recent times,but the im
197、pact of the climate emergency has the potential to be greater still and is already changing our planet irreversibly.The impact of climate change includes increasing levels of ill health,including a rise in chronic conditions e.g.heart disease,stroke,lung cancer and respiratory diseases.4 All of thes
198、e have detrimental impacts on peoples lives and the societies and economies in which we live.As a sector we must do more approximately 4%of global greenhouse gas(GHG)emissions come from the healthcare sector,from pharmaceutical manufacturing to hospitals.5 So everyone involved in the delivery of hea
199、lthcare has a role toplay.Description Achieve net zero greenhouse gas emissions by maximising our energy efficiency,shifting to renewable energy sources,and investing in nature-based removals to compensate for any residual GHGfootprint Build resilience by managing the physical(sites,supply chain)and
200、 transitional(regulatory,market and product)risks and opportunities arising from climate change in the value chain through adaptation and business continuity planningApproachWe follow the science and focus our activity on delivering absolute reductions in all our direct and indirect GHG emissions so
201、urces across the value chain Scopes 1,2 and 3.We will reach our targets by:Decoupling our energy consumption from business growth achieving absolute reductions in total energy consumed and doubling energy productivity from 2015 baseline(EP100),through continued investment from the Natural Resource E
202、fficiency Fund Substituting 100%of site energy consumption with renewables(RE100)and maximising the share of additional sources of renewable electricity,for instance through on-site solar PV and off-site power purchase agreements(PPAs)Transitioning 100%of self-generated and imported heating and cool
203、ing to renewables,maximising the share of additional sources of clean heating and cooling,for instance on-site technology and new off-site biomethane production Reducing the emissions of our legacy fleet and switching to a fully electric vehicle fleet(EV100)Transitioning to our next-generation respi
204、ratory inhalers with near-zero climate impact propellants Engaging with our suppliers to reduce emissions in line with the science of climate change Assess and mitigate the physical and transitional risks to our business caused by climate change,integrate these risks into overall risk management pro
205、cesses and report on them through our TCFD reportPursuing a science-based climate strategyThrough our flagship$1 billion Ambition Zero Carbon programme we are on track to reduce greenhouse gas emissions from our global operations(Scope 1 and 2)by 98%by 2026(from 2015 baseline)and halve our entire va
206、lue chain footprint by 2030 on the way to a 90%reduction by 2045(from 2019 baseline).Our emission reduction targets have been verified by the Science Based Targets initiative(SBTi)and we were one of the first seven companies worldwide to have our net zero,science-based Scope 1-3 targets verified und
207、er their new Net-Zero Corporate Standard.We were also an early supporter of the UN-backed Race to Zero.Ambition Zero Carbon2026 target98%absolute reduction of Scope 1 and 2 GHG emissions from 2015 base yearStatus:On Plan2021 progress59%Scope 1 and 2 GHG emissions reduction,including 9%reduction in e
208、nergy consumption62030 target50%absolute reduction of Scope 3 GHG emissions from 2019 base yearStatus:On Plan2021 progress15%GHG increase in total Scope 3 emissions,including a 17%decrease in Scope 3 emissions relative to revenue;7%of spend in purchased goods and services and capital goods with comp
209、anies with approved SBTs6,7Key targets and progressAmbition Zero CarbonAstraZeneca Sustainability Report 2021 20Environmental protectionSee Sustainability Data Summary forfull metrics and methodologyAccess to healthcareEthics and transparencySustainability overviewNoticesWe will follow the science a
210、nd deliver absolute reductions in all our direct and indirect sources,Scopes 1,2 and 3,of greenhouse gas(GHG)emissions across our value chain,doing our part to limit the impacts of climate change while unlocking opportunities to deliver improved patient centric healthcare in a low carbon economy.Amb
211、ition Zero Carbon204520302002320242025202620282027Scope 1&2Emissions from our own operations(site and fleet)Target baseline emissions(2015):0.65M tCO2eScope 3All other indirect emissions that occur in our value chainTarget baseline emissions(2019):5.7M tCO2eLaunched Ambition Zero CarbonFi
212、rst pharma to join all 3 of Climate GroupsSigned up to UN Race to Net ZeroSBTi verify Scopes 1,2,3 and Net Zero targetsLaunched the Energize programmeLaunched the Product Sustainability IndexHoneywell Partnership announced for low GWP propellants7%of suppliers have SBTsFuel and energy-related activi
213、ties,upstream leased assets reduced by 80%46%reduction in purchased goods and servicesFootprint from patient use of sold products(e.g.inhalers)reduced by 95%;end of life treatment of sold products reduced by 46%Reduce absolute scope 3 GHG emissions 90%by FY2045 from a FY2019 base year$130M invested
214、in natural resource efficiency projects since 201559%reduction in GHG since 2015100%imported renewable electricity globally2%EV;57%green fleet(EV,hybrid or plug-in hybrid)Agreement signed with Future Biogas for renewable heat in UK We follow a hierarchyto achieve our ambitions Eliminate Reduce Subst
215、itute Compensate SBTi VerifiedScope 1&2 reduction targets are measured from a 2015 base year.Scope 3 reduction targets measured from 2019 base yearFirst climate impact disclosure to TCFDACHIEVEDReduce absolute Scope 1 and 2 GHG emissions 98%by FY20262026 TARGETACHIEVEDACHIEVEDACHIEVEDScope 3 Baselin
216、eScope 1&2 Baseline2030 TARGET2045 TARGET20202029Supplier engagement to measure and report GHG footprintReduce absolute scope 3 GHG emissions 50%by FY2030Remove more CO2 from the atmosphere than we emit from 2030,to be carbon negative Compensate for any residual Scope 1 and 2 emissions through high
217、quality removals using BECCSContinue to decarbonise the full value stream of our business in line with the 1.5C pathwayEliminate future emissions sources from new assetsOur Scope 1&2 priorities and actions fall into four categories:FleetHeatElectricityF-gases&OtherOur Scope 3 priorities cover:Purcha
218、sed goods and servicesCapital GoodsUpstream and downstream transportation and distributionWaste generated in operationsBusiness travel and employee commutingUpstream and downstream leased assetsUse of sold products and their end-of-life treatment2025 TARGETSBTs covering95%of suppliers by spend,cover
219、ing purchased good and services and capital goods50%of suppliers by spend covering transportation,distribution and business travelLaunch our first next generation inhaler with low or near-zero GWP propellants by 2025END OF 2025 TARGET Substitute F-gases for low GWP alternativesSubstitute natural gas
220、 consumption with renewable sources of heat and powerReduce and capture F-gas emissions from where we make respiratory medicinesTransition to next generation inhalers across our portfolio 2021Invest in nature-based removals Continue to switch from air freight to sea and rail freight,minimise busines
221、s air travel,and transition management cars to electric vehiclesAmbition Zero CarbonEnvironmental protectionAstraZeneca Sustainability Report 2021 21Access to healthcareEthics and transparencySee Sustainability Data Summary forfull metrics and methodologySustainability overviewNoticesSustainability
222、in actionAZ Forest Restoring forests and biodiversity AZ Forest is our global initiative to plant and maintain 50 million trees worldwide by the end of 2025,in partnership with local governments and non-profit organisations that are focused on global reforestation and building ecological and communi
223、ty resilience.Reforestation helps sequester carbon dioxide,prevent disease through combatting air pollution and supports the restoration of biodiversity.Planting trees also helps to reduce the risks of natural disasters,has social and economic benefits for communities,and promotes physical and menta
224、l wellbeing.Our AZ Forest programme is also part of our work to address climate change,and we support the WEFs 1t.org The Champions for a Trillion Trees platform.In 2021,AZ Forest was active in the following countries,working alongside our global partner One Tree Planted:Indonesia,where we have comm
225、itted to plant 20 million trees by 2025 Australia,where we have pledged to plant 25 million trees,recognising the impact of the devastating bushfires in 2020 United Kingdom,where we will plant over one million trees across England and southern Scotland by 2025HighlightsBuilding climate resilience in
226、to our supply chainPhysical risks from climate change have been screened for in more than 550 locations in our supply chain,including our own sites and those of almost 350 strategic suppliers.We conducted detailed site-level assessments in 2021.Outcomes indicate potential for a)need to maintain a co
227、ntrolled environment as required by Good Manufacturing Practice,b)heavy rainfall causing local flooding and/or inducing landslides,c)high wind events that can damage site structures.A full TCFD report is available with the details of our assessments.Scope 3 Supplier EngagementWe are working to build
228、 transparent supply chains by asking our partners to assess anddisclose their greenhouse gas emissions to the CDP Supply Chain Programme,recognising the value of the platform inproviding comparable climate-related data,a necessary first step toward meeting our Scope 3 goals.We look for opportunities
229、 to engage with our suppliers to reduce emissions across the value chain.We invited our top 250 suppliers to participate and more than 70%of those suppliers disclosed their climate change data,including many suppliers who had never disclosed toCDP before.Membership of this programme will accelerate
230、supplier engagement.Energize ProgrammeAn exciting example of collaboration is the partnership we announced at COP26 together with industry peers and Schneider Electric to help our suppliers access renewable energy.The Energize programme will support the decarbonisation of healthcare across the indus
231、try by facilitating the provision of and access to renewable power at scale for our suppliers.Clean PowerIn 2021 we transitioned to 100%imported electricity from certified renewable sources.We recognise the many benefits of self-generated renewables to site energy costs,resilience and employee engag
232、ement and have committed$20M over 2020-2023 in on-site solar PV installations at six sites in five countries.Once all these investments are completed,the total output is estimated to be 14,400 Megawatt hours(MWh),equivalent to around 2%of our imported electricity needs.There is a limit to the scale
233、that can be achieved through on-site solar PV and so to deliver additional renewables we are aiming to meet the majority of our electricity needs in our primary consumption locations Sweden,US and US through power purchase agreements(PPAs)by the end of 2025.Mount Vernon,Indiana,Solar FieldThis proje
234、ct includes a$3.5M investment in 2021 in a 2MW,seven-acre solar field project at our Mount Vernon,Indiana manufacturing facility in the US.The output from the solar field meets 10-15%of the sites electricity demand,displacing the cost of importing the electricity while also reducing our energy suppl
235、y emissions and improving site energy resilience.Clean Heat Access to certified low and zero carbon fuels and imported heating and cooling sources globally is very limited,and we are striving to develop new sustainable sources in order to achieve our Ambition Zero Carbon targets.Partnership with Fut
236、ure Biogas In the UK we have partnered with Future Biogas to build a new renewable energy plant to generate biomethane as a substitute for natural gas.This initiative will add new renewable capacity to the existing UK gas grid,with the capacity to provide up to 125 Gigawatt hours(GWh)of biomethane,e
237、quivalent to the energy demand to heat over 9,000 homes.The new plant will utilise energy crops as the feedstock,grown as part of a regenerative farming rotation and not at the expense of food production.In fact,the digestate by-product of the biomethane production process is a nutrient-rich fertili
238、ser that can be used locally to enhance soil health and displace fossil fuel-based fertilisers,supporting the circular economy in the UK.Construction will begin in 2023 and the installation will supply a significant proportion of our UK biomethane needs by 2025.Not only will this support our Scope 1
239、 emission reductions,but the biogenic CO2 generated by the anaerobic digestion of the energy crop will be captured,compressed,and put into permanent storage in underground rock formations in the UK North Sea.This innovative process is known as BECCS bioenergy with carbon capture and storage.Deliveri
240、ng on our renewable energy strategySince 2015,we have invested$130M in natural resource efficiency and renewable energy at our sites through our dedicated fund.We will always need some energy and we are committed to using 100%renewable energy sources to meet all our needs by the end of 2025.In 2021,
241、we initiated a programme of work to look at how we can maximise the positive impact of our renewable energy use,with a focus on adding new renewable energy sources to the locations that we operate in.AstraZeneca Sustainability Report 2021 22Environmental protectionAmbition Zero CarbonAccess to healt
242、hcareEthics and transparencySustainability overviewNoticesProduct sustainabilityWhy it mattersPeople and the planet benefit from medicines with the smallest possible environmental impact,while maintaining medical efficacy and safety.As technologies and healthcare systems evolve,so too should solutio
243、ns to reduce energy,water,material use,waste and pollution generated from designing,manufacturing,and delivering medicines topatients.We are responsible for our choices in raw materials sourcing,manufacture,and formulation of active pharmaceutical ingredients(APIs),as well as device and packaging se
244、lection.As we improve our processes,we can implement change ahead of evolving regulations,and reduce costs of supply.This allows us to reinvest in life-changing medicines and improve patient access to affordable healthcare solutions.DescriptionWe follow processes throughout the lifecycle of our prod
245、ucts with the aim of understanding and minimising their environmental impact;from discovery through development and production,to launch of a new product and end-of-use.ApproachTo deliver medicines that improve patient outcomes with the lowest possible burden on the planet,we evaluate materials and
246、processes used to make our products across the entire value chain and proactively investigate opportunities to reduce their impact.We also lead our industry in the management of Pharmaceuticals in the Environment(PIE)striving to address critical scientific knowledge gaps and promote responsible prod
247、uct stewardship.We have well-established programmes to embed sustainable decision-making and quantify environmental improvements across the product life cycle that include:Integrated business processes to ensure safety,health and environmental aspects are considered by projects throughout drug devel
248、opment with detailed guidance for environmental assessment of API manufacturing,formulation,packaging,and devices Maximising the resource efficiency of our API manufacturing processes Life cycle assessment(LCA)programme to determine the type and magnitude of environmental impacts across our product
249、value chains in line with ISO standards 14040 and 14044 Active pharmaceutical ingredient(API)discharge programme and related targets for AstraZeneca and our external supply sites Ongoing post-approval ecopharmacovigilance(EPV)to track the environmental risks that result from patient use of our produ
250、cts Conducting research to understand the environmental impact of our products and embed the principles of green chemistry within our business Partnering to drive thought leadership and innovation,for example leading the Innovative Medicines Initiative(IMI)PREMIER project,a public-private partnershi
251、p between the European Commission and the European Federation of Pharmaceutical Industries and Associations(EFPIA),which aims to develop tools to identify potential environmental risks of APIs earlier in drug development and make these tools and data more visible and accessible to all stakeholdersCh
252、allengesPressurised metered-dose inhalers(pMDIs)rely on fluorinated gases(F-Gases)as a propellant and tighter regulation could put future revenue at risk,if the alternatives we are actively researching are not successful or cannot be substituted into the product.Loss of the medicinal quota exemption
253、 for HFA propellants,or failure to have a long-term phased transition,could prevent or limit availability of products in our inhaled medicines portfolio,should these restrictions become applicable before the transition to our next-generation lowglobal warming potential(GWP)pMDIs.Complementing the Eu
254、ropean Commissions pollution reduction strategy,proposed updates and changes to pharmaceutical and chemicals regulations could influence the way medicines are manufactured and approved in future.Monitoring these regulatory risks and proactively managing the chemicals used in our processes will help
255、minimise the impact on access to medicines for patients.2025 targetEnsure 90%of active pharmaceutical ingredient(API)syntheses meet resource efficiency targets at launchStatus:Lagging2021 updateSince 2015,75%of projects(three of four)have met defined resource efficiency targets.8 In 2021 a new oncol
256、ogy medicine met its Process Mass Intensity10(PMI)target at launch and we achieved a PMI reduction of 14%across the late stage project portfolio2022 targetEnsure 100%of AstraZeneca owned and 90%of supplier site discharges are in compliance with safe API discharge concentrationsStatus:On Plan2021 upd
257、ate100%of API discharges from AstraZeneca sites demonstrated as safe.1 91%of API discharges from globally managed direct suppliers demonstrated as safe1,2,3 Key targets and progresspatient use packagingdistributionAPI production and formulationdevice productiondisposal(end-of-life orreuse)We follow
258、a life cycle approach that covers all stages of our productsAstraZeneca Sustainability Report 2021 23Environmental protectionProduct sustainabilitySee Sustainability Data Summary forfull metrics and methodologyAccess to healthcareEthics and transparencySustainability overviewNoticesSustainability in
259、 actionCollaboration to accelerate development of novel next-generation therapeutics to patients In 2021,we started a Grand Challenge collaboration as part of the Medicines Manufacturing Innovation Centre where we are a founding partner.We are partnering with CPI,Exactmer,Novartis,Alnylam and UK Res
260、earch&Innovation,to advance the sustainable development of new manufacturing processes for oligonucleotides:short strands of synthetic DNA or RNA.These molecules have a wide range of applications,including in genetic testing and research.The collaboration aims to make the production of oligonucleoti
261、de therapeutics scalable and more cost-effective,ultimately accelerating delivery of this novel next-generation therapeutic to patients.Our recent advances in genomics,and the discovery of promising new targets with detailed genomic information,are driving the design of oligonucleotides with the pot
262、ential for targeted therapeutic interventions across our therapy areas.However,finding new ways of increasing production of oligonucleotides is a significant industry challenge.The collaboration will bring expertise to transform the oligonucleotide supply chain.In parallel,the collaboration partners
263、 are sharing best practice in oligonucleotide chemistry and analytics,as well as process engineering.Demonstrating the environmental safety of our medicines followingpatient useIn Europe and the United States,an environmental risk assessment(ERA)is conducted when a medicinal product is ready for com
264、mercialisation.This generates environmental risk information for relevant environmental compartments(e.g.surface waters and sediment)based on a predicted environmental concentration and a no effect or safe concentration for the active pharmaceutical ingredients(APIs)in that medicinal product.We have
265、 run an ecopharmacovigilance(EPV)programme since 2012,systematically searching for environmental data on our APIs in order to better understand the risk our medicines could pose to the environment from patient use.In 2021,we launched an EPV dashboard that shows the relative risks of APIs that have b
266、een shown to reach the environment the first pharmaceutical company to share these data.Using this interactive dashboard,users can compare in excess of 25,000 individual measured environmental concentrations with known no effect safe concentrations,helping to identify and manage any associated risk.
267、Launch of a Product Sustainability IndexFollowing work in 2020 to develop the methodology,we launched an internal Product Sustainability Index(PSI)in 2021 to advance product environmental performance and innovation across our therapy areas.An extensive pilot was conducted for four brands including o
268、nemonoclonalantibody.To embed the PSI globally,a cross-functional product sustainability workstream has been established to ensure relevant business processes across the organisation integrate product sustainability considerations and drive improvement.Our goal is for all our products to be assessed
269、 against the PSI to track their environmental sustainability and inform environmentalimprovement plans for our project teams.Highlights Transitioning to our next-generation respiratory inhalers with near-zero climate impact propellants A key product-related element of our Ambition Zero Carbon strate
270、gy is our commitment to develop the next-generation respiratory inhalers with near zero global warming potential(GWP)propellants.In 2021 we achieved positive results from a first in human Phase I trial,and AstraZeneca will now advance a partnership with Honeywell to develop and commercialise respira
271、tory therapies with the near-zero GWP propellant,HFO-1234ze.Waste stream assessment methodology in Pharmaceutical Technology and DevelopmentLife cycle assessment(LCA)has shown that solvents can be more than 70%of an APIs environmental footprint.Aninnovative waste stream assessment has been introduce
272、d by our development scientists to help realise the transition to circular manufacturing and reduce the environmental burden from solvent usage.The framework facilitates the assessment ofwaste streams for suitable technologies for recycling,reuse and reduction of solvents.Identifying opportunities f
273、or CO2 reduction in clinical trialsWe have conducted LCAs of clinical trials across therapy areas to identify CO2 hot spots and opportunities for reduction including travel,samples and waste.Learnings were incorporated into a framework for clinical trial design and in our existing governance process
274、,in order to ensure CO2 reduction is always considered in clinical drug development.Awareness and training has been shared across R&D.Carbon:greenhouse gas(GHG)footprint of a productacross the whole value chain,per patient,peryearPower:percentage of renewable electricity,not including energy supplie
275、dforheating,used in manufacture across aproducts supplychainWater(resource):water consumption across the whole valuechain,perpatient,per year Water(releases):risk of API discharges tothe environment resultingfrom patient useand manufacturingResource use:use of raw materials indrug substance manufact
276、ureInnovation and improvement:improvements made across the five categories above,driven by innovative approaches during the productlife cycleThe PSI has scoring criteria acrosssixcategories:Environmental protectionProduct sustainabilityAstraZeneca Sustainability Report 2021 24Access to healthcareEth
277、ics and transparencySustainability overviewNoticesWhy it mattersWe need to shape a resilient,sustainable and healthy future for people and the planet.We should work on the basis of harmony between society and the natural environment.We will only achieve sustainable wellbeing by acting to protect,sus
278、tainably manage and restore ecosystems that support a healthy and resilient society.We invest in nature and biodiversity to benefit both planetary andsocietal health.DescriptionNatural resources are essential to produce our medicines and operate our sites.We are committed to:Reducing our impact on t
279、he planet through the efficient,circular use of water and other natural resources across the value chain to ensure responsible sourcing,consumption,production and disposal Protecting and restoring ecosystems to improve health outcomes and tackle environmental drivers of disease,such as water and air
280、 quality,through our focus on water stewardship and biodiversityApproachOur key targets aim to decouple water use and waste generation from business growth,supported by efficiency projects and our Product sustainability work.Integrating a circular mindset will help us to keep raw materials in use an
281、d design out waste and pollution.Minimising resource use and waste generation supports our goals to protect biodiversity and reduce Scope 3 emissions as part of Ambition Zero Carbon.As well as contributing to our work to tackle climate change,our AZ Forest commitment will bring many co-benefits,incl
282、uding developing more sustainable livelihoods,fostering biodiversity and building climateresilience.We aim to integrate a circular economy approach across our value chain.We are leveraging our experience with Lean manufacturing,which includes tools to enhance efficiency and eliminate waste,to build
283、a framework for employees to identify and implement ideas that contribute to our environmental targets.Water stewardshipWater is fundamental for all life and in our Water Stewardship Position Paper we outline our plans to positively contribute to water stewardship in the river basins where we operat
284、e,supported by our water stewardship partnership with the World Wide Fund for Nature(WWF)Sweden.In 2021,we introduced a water stewardship pilot to build on our experience,focusing on efficient water use within the boundaries of our sites,along with water quality and collective action opportunities i
285、n the local basin.We have prioritised six sites located in water scarce areas across five countries,as these face increasing water availability and quality risks as climate change impacts the global water cycle.In 2022,we will set locally-appropriate water targets for these sites and aim to have lon
286、g-term contextual water targets in place by 2025,which will help mitigate site-specific risks and support shared local water challenges.This will support our transition to Science-Based targets for water once the methodology is available.The programme is supported by ongoing water audits and risk as
287、sessments,including WWFs water risk filter tool.ChallengesOur focus on patient centricity to deliver products to patients as quickly as possible,along with the complex regulations for our industry,can pose a challenge for us to design or redesign our processes and products for circularity.We continu
288、e to focus on targeted innovation to find solutions that support both patients and our planet in partnership with our external manufacturing suppliers.The pharmaceutical sector uses many materials which are hard to recycle but difficult to replace.It also generates waste streams that are difficult t
289、o reuse,recycle or repurpose as they are considered to be hazardous in nature.These factors mean cross-sectoral collaboration with regulators and the recycling industry will be needed if we are to achieve the vision of creating a circular business.Key targets and progressNatural resources2025 target
290、Maintain absolute water use at 2015 baseline levelsStatus:On Plan2021 updateWater footprint was 3.82 million m3,a 17%reduction from 2015102025 targetReduce waste by 10%below the 2015 baselineStatus:On Plan2021 updateTotal waste was 28,848 tonnes,down 7%from 30,942 tonnes in 20209,representing a decr
291、ease of 8%from 2015Develop suitable metrics to monitor our progress towards a more circular economyMaximise proportion of waste recycled and aim to eliminate waste to landfillIncorporate the principles of the circular economy into the design of all our processes and products,from initial research an
292、d development through to productionIncrease reused or recycled content of the materials we use(both directly,and in our supply chain)Where possible,regenerate nature and use renewable natural resources instead of non-renewable onesSeek to minimise the amount of materials required and waste generated
293、 during manufacture and use of our productsOur circular economy approach:Natural resourcesAstraZeneca Sustainability Report 2021 25Environmental protectionSee Sustainability Data Summary forfull metrics and methodologyAccess to healthcareEthics and transparencySustainability overviewNoticesSustainab
294、ility in actionHighlightsCDP A List for Climate and Water and C for Forest Our leadership in tackling climate change and protecting water security has been recognised by CDP-worldwide with a double A rating,for the sixth consecutive year.2021 also saw us triple-rated for the first time.We received o
295、ur first published CDP Forests rating our risk management of forest related commodities:timber,cattle and palm oil was C-rated.To improve sustainable timber product use,we have committed to achieve 95%sustainable paper in secondary and tertiary packaging by the end of 2022 and we are looking to redu
296、ced our timber requirements by shifting to reusable pallets.We use a relatively small volume of cattle and palm oil derivatives in our products.Our approach to managing risks in this area can be seen in our Forestry Statement.Zero Waste Certification Our R&D site in South San Francisco has achieved
297、Platinum Level TRUE zero waste certification.The TRUE certification programme is administered by the Green Business Certification Inc.(GBCI).It recognises effective resource management by verifying compliance with all applicable programme requirements.This is the first of our sites to achieve this c
298、ertification level.WWF study into pharmaceutical sector water riskArising from our water stewardship partnership,WWF conducted a case study that helped identify sectoral-level water stewardship opportunities and what potential shared water challenges may be strategically relevant in areas of concent
299、rated pharmaceutical manufacturing.The study presents the sector with recommended next steps.Wastewater reuse at Wuxi During our water risk assessment process,our site in Wuxi,China,was identified as being at increasing risk of water scarcity and declining quality,between 2020 and 2030.A water audit
300、 identified a projected saving of 24,750 m3 annually about 10%of site water usage and the equivalent of approximately ten Olympic-sized swimming pools by installing a wastewater treatment plant on site and reusing treated wastewater for other critical operations,including in the site cooling towers.
301、The reuse water generator and distribution equipment has been installed,with project completion expected in 2022.This project shows how working to improve circularity at our sites can reduce reliance on natural resources and improve water quality.Site water reduction initiative in Ireland Our Rare D
302、isease Groups site in College Park,Ireland,a top water user in our site network,identified several water reduction opportunities:The facility requires highly purified water.By creating new recirculation flowrate parameters that optimised the generation process,the amount of rejected Ultra Filtered W
303、ater reduced by 27%,saving up to 16,200 m3 annually Vessel cleaning cycles were modified to remove additional steps after studies were performed to determine they provided no additional cleaning benefit.The adjusted cycles reduced the chemical cleaning agent by 83%and the water by 45%.Based on the t
304、ypical production schedule this saves at least 12,500 m3 annually.By reducing the amount of purified water,and time of the cleaning cycles,there are additional energy savingsSwitching to paper-based trays to reduce single use plastic We are switching from plastic to paper-based trays to secure our p
305、roducts within cartons.By making this change in one of our respiratory products,we avoided the use of 194,832 single use plastic items in markets including the US,Central America and the Caribbean in 2021.Assuming the inserts are recycled when disposed of,this change results in a reduction of 4%in t
306、he overall greenhouse gas emissions from this product.We are working to expand this initiative into other markets,including Europe.Other products are also launching with these paper-based trays,avoiding millions of single use plastic items in our packaging,as we deliver more medicines to patients.Im
307、proving the environmental impact ofour lab operationsIn 2021,our partnership with the non-profit organisation,My Green Lab,continued to inspire a reduction in the environmental impacts of our lab practices.A total of 36 laboratory functions across 31 sites are involved in the programme.12 were certi
308、fied across 11 sites:four achieved the highest Green certification level,one Platinum,six Gold and one Silver.For the second consecutive year we won the Biotech/Biopharma organisation category in the International Freezer Challenge,saving around 1858 kWh/day across the participatingsites.My Green La
309、b certification has been recognised by the pharmaceutical sector as part of the UNFCCC Race to Zero.My Green Lab:36 laboratory functions across 31 sites1Platinum4attained the highest Green certification level6Gold1SilverAstraZeneca Sustainability Report 2021 26Environmental protectionNatural resourc
310、esAccess to healthcareEthics and transparencySustainability overviewNoticesEthics and transparencyEquality and prosperity for all fosters healthy societiesContributing to the Sustainable Development Goals,a universal blueprint for prosperity forpeople and the planet,now and intothe future.SDG 3|Good
311、 health and well-beingSDG 5|Gender equalitySDG 8|Decent work and economic growthSDG 17|Partnerships for the goals50.9instances of non-compliance with the Code of Ethics per thousand employees in commercial business units248.1%women in senior middle management roles and above33countries launched new
312、supplier diversity programmes85%of employee survey respondents feel that AstraZeneca is a Great Place toWork83%of employee survey respondents feel that AstraZeneca has aSpeak Up1 cultureOur ambition:Ensuring ethical,open and inclusive behaviours across our organisation and value chainConnection to h
313、ealth:Fostering a culture of doing therightthing across our valuechain promotes health andwellbeingOur material focus areas2021 performance:Ethics and transparencyAstraZeneca Sustainability Report 2021 27Ethics and transparencySee Sustainability Data Summary forfull metrics and methodologyAccess to
314、healthcareEnvironmental protectionEthical business cultureInclusion and diversityWorkforce safety and healthSustainability overviewNoticesGovernanceOur commitment to Ethics and transparency underpins everything we do and runs through our culture and ways of working.All of our employees contribute to
315、 the delivery of our Ethics and transparency material focus areas,which are governed across several areas:Human Resources,Operations,Legal,R&D and Global Sustainability.Where these overlap,we work cross-functionally to manage delivery of strategy and outcomes.Our unified quarterly scorecard tracks 1
316、1 Ethics and transparency metrics and communicates our performance on these to our employees.We seek to create positive societal impact and embed ethical behaviour in all our business activities,markets and value chain.We do this by promoting ethical,transparent,and inclusive policies and practices,
317、both within our company as well as across all our partners and suppliers.The big picture There is a lack of public trust in big corporations including towards companies in the pharmaceutical industry which can have a negative impact on our ability to operate,innovate and bring healthcare solutions t
318、o more people.We operate in a highly regulated environment,and AstraZeneca as a company has maintained a high profile in 2021 with the COVID-19 pandemic and our work on the vaccine.We must retain and increase trust across all of our stakeholder groups,continuing to deliver life-changing medicines to
319、 patients whatever the futureholds.ApproachIts important that we create value beyond the impact of our medicines on patients.Building trust by demonstrating integrity,transparency and fair treatment is central to everything we do.Our shared Values underpin all our activities and serve as a compass t
320、o guide us in all that we do.Ethics and transparency overview AstraZeneca Sustainability Report 2021 28Material focus areasWe follow the scienceWe put patients firstWe play to winWe do the right thingWe are entrepreneurialOur ValuesEthics and transparency overviewEthics and transparencyAccess to hea
321、lthcareEnvironmental protectionEthical business cultureInclusion and diversityWorkplace safety and healthSustainability overviewNoticesWhy it mattersAn ethical business culture is an imperative against a background of reputational,legal,regulatory and long-term sustainability risks,and we are commit
322、ted to increasing public trust in our industry.DescriptionDrive the highest standards of conduct and accountability beyond compliance,including,but not limited to,anti-bribery and anti-corruption,product safety,use of human tissue and animals for research,human rights,and building supplier capabilit
323、ies to uphold high socialstandards.ApproachThe key elements of our commitment to an ethical business culture are:Our Code of Ethics and Values,which guide everything we do and ensure that we deliver life-changing medicines in a responsible way.Additional requirements at the local and business-unit l
324、evels complement our Code Values-based decision making.We know that setting rules is not enough which is why we emphasise Values-based decision making.We encourage our workforce to adopt a sustainability mindset that embraces our core Values Being visible and transparent about our business.In todays
325、 information-seeking society,our actions add more value by being visible.Transparency supports learning and development for our employees,suppliers and partners.It also meets expectations of patients,investors andbroadersociety Human Rights As a healthcare company,we believe health is a human right
326、and,therefore,enabling access to our medicines is vital.Beyond our core business of health,it is our responsibility to understand how we are contributing to or protecting human rights due to our operations.This includes taking action on issues such as modern slavery,workforce treatment,labour rights
327、 and data privacy.We aim to prevent human rights violations by proactively identifying any risks in our business and responding promptly with appropriate action.As signatories to the UN Global Compact(UNGC)for the past 11 years,we commit to the Guiding Principles to respect human rights by acting wi
328、th due diligence to avoid infringing on human rights and to address negative impacts.We are also committed to the International Labour Organization(ILO)standards on child labour and minimum working age.Responsible Supply Chain We interact with an extensive network of suppliers globally,and this reac
329、h gives us the opportunity and responsibility to promote practices with our suppliers that are socially and environmentally sustainable.Our business success depends on a resilient,transparent and inclusive supply chain that supports responsible sourcing,development and manufacturing.Embedding sustai
330、nability through collaboration with our suppliers increases business value for all.Throughout the lifetime of our relationship with each supplier,we seek to ensure that their conduct matches the expectations outlined in our Global Standard Expectations of Third Parties.We aim to work only with suppl
331、iers whose values are consistent with our own and who are committed to developing inclusive,resilient and transparent businesses.ChallengesWith the speed of scientific and technological developments,it is important that we remain aligned with evolving regulations and stakeholder expectations.This is
332、 especially true in the case of Artificial Intelligence(AI),where technological progress is ahead of regulation.We encounter new ethical considerations with our growing pipeline and scope of operations,for example new privacy regulations in China and theEU.Key target and progressEthical business cul
333、ture2025 targetMaintain 100%of active employees trained on the Code of EthicsStatus:On Plan2021 update100%of active employees trained on the Code of Ethics in 2021 2025 targetImprove the AstraZeneca global biannual human rights survey by using Fair Wage Network data to more robustly assess our performance against local living wage dataStatus:Not Yet Started 2021 updateThe human rights survey is bi